According to the communication and information center in the Vice Presidency of Science, Technology and Knowledge-Based Economy, the Biotechnology Development Center at the National Research Institute of Genetic Engineering and Biotechnology, was opened and put into operation this afternoon in the presence of Ruhollah Dehghani, the Vice President of Science, Technology and Knowledge-Based Economy, Zolfi Gol, Minister of Science, research and technology and a group of biotechnology activists.

On the sidelines of the opening ceremony of this center, the vice president of science, technology and knowledge-based economy stated that in recent years, great and valuable steps have been taken in the development of biotechnology technology and economy by experts, researchers and technologists, and stated: Today, the production of biotechnological, recombinant and capability in the production and development of human and animal vaccines and the penetration of biotechnology in the agriculture and food industry are among the most prominent indicators of Iran's technological superiority in the international arena. This importance has been achieved with the help of many years of efforts of researchers and activists in the field of technology development and biotechnology economy.

Dehghani continued: Fortunately, the scientific and technological movement of the country is moving forward with good speed and acceleration. This research center, which has provided a suitable platform for establishing the activities of more than 30 knowledge-based companies in a space of seven thousand square meters, has been revived with the cooperation of the research institute and the role of the private sector, and with the help of this center, I hope that biotechnology and the production of pharmaceutical products based on this technology, take another serious step forward.

Dehghani considered the creation of necessary platforms for production and value creation based on technologies as one of the serious priorities of the Vice Presidency for Science, Technology and Knowledge-Based Economy and continued: Knowledge-based companies operating in the private sector should be able to create value in synergy with the public sector. Increase employment and the economy.

He pointed out that production and development based on innovation is one of the characteristics of today's knowledge-based economy manifested in the form of this center, and this approach is supported by the Vice Presidency of Science, Technology and Knowledge-Based Economy, he continued: with the efforts and participation of the private sector. An abandoned building with an age of more than 30 years, which was on the verge of destruction, was prepared in less than seven months, and today it has become a platform for the gathering of knowledge-based companies that move in the frontiers of knowledge and develop the most advanced medicines and necessities in the field of health.

Creating a complete chain of ideas to the biotechnology market

The Biotechnology Development Center has started its activity in the heart of a 7500 square meter building in one of the departments of the research institute, while the restoration, redesign and preparation of the building has been done by the private sector and technology activists of the companies located in this center.

Seven hundred square meters of the Biotechnology Development Center building is dedicated to the Technology Accelerator Laboratory and clinical, specialized and research tests are carried out in this complex. In the first phase of this project, the capacity to deploy and employ 300 people, who are mainly specialists in biotechnology, cellular, molecular and pharmaceutical fields, and with the launch of the next phase, this capacity will increase to 500 people.

It should be noted that the building that was put into operation today was unused for more than three decades and was put into operation with the investment and efforts of private sector activists.

This infrastructure set has created an infrastructure for bringing together all the links of the value chain of the pharmaceutical and biotechnology industry and is supposed to form the link between the idea and the market in the field of medicine, food industry and human vaccines.